Published 7 months ago • loading... • Updated 7 months ago

Breast Cancer Scientific Study Breakthrough for New Antibody Treatment

On October 23, 2025, researchers at King's College London reported a novel antibody that attacks tumour cells and harnesses the body's immune defenses, publishing their findings in Cancer Research journal.
Triple-Negative breast cancer lacks receptors for oestrogen, progesterone and HER2, making hormone therapies and HER2 drugs ineffective and leaving patients with fewer treatment options and higher recurrence risk.
Preclinical studies found the antibody bound immune cells more strongly and activated immune cells within tumours and circulating immune cells in lab and animal studies.
The research team at King's College London says the therapy could provide new options for treatment-resistant cancers, including triple-negative cases, and might extend to ovarian and endometrial cancers; further lab optimisation tasks are under way to extend antibody lifespan and broaden immune activation before clinical trials.
This early-stage research offers hope for over 8,000 women in the UK diagnosed with triple-negative breast cancer, which accounts for around 15% of all breast cancers and affects younger women and Black women more.

Insights by Ground AI

43 Articles

Antibody Breakthrough Offers Hope for Treatment-Resistant Breast Cancer Patients

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients. It may be able to treat some of the most aggressive forms of the deadly disease, say researchers at King’s College London who designed the new antibody that not only attacks the tumor cells directly, but also harnesses […] The post Antibody Breakthrough Offers Hope for Treatment-Resistant Breast Cancer Patients appeared first…

7 months ago·United States

Read Full Article